On the public citation graph
The future of bypassing agents for hemophilia with inhibitors in the era of novel agents
0 signed · 147 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ajh.2830470312openalex-snapshot
Inhibitors in hemophilia patients: Current status and management
inferredcites →https://doi.org/10.1007/s40265-018-0922-6openalex-snapshot
Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab
inferredcites →https://doi.org/10.1016/j.bcmd.2015.11.004openalex-snapshot
Heterozygous congenital Factor VII deficiency with the 9729del4 mutation, associated with severe spontaneous intracranial bleeding in an adolescent male
inferredcites →https://doi.org/10.1016/j.thromres.2009.11.003openalex-snapshot
Factor V Leiden and hemophilia
inferredcites →https://doi.org/10.1016/j.thromres.2012.08.305openalex-snapshot
PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors
inferredcites →https://doi.org/10.1016/s0049-3848(16)30359-0openalex-snapshot
Targeting TFPI for hemophilia treatment
inferredcites →https://doi.org/10.1016/s0268-960x(03)90000-2openalex-snapshot
A cell-based model of coagulation and the role of factor VIIa
inferredcites →https://doi.org/10.1016/s0268-960x(15)30006-0openalex-snapshot
Safety update on the use of recombinant activated factor VII in approved indications
inferredcites →https://doi.org/10.1046/j.1365-2516.2003.00771.xopenalex-snapshot
Long‐term FEIBA prophylaxis does not prevent progression of existing joint disease
inferredcites →https://doi.org/10.1055/s-0037-1613110openalex-snapshot
Pulmonary Embolism After Sequential Use of Recombinant Factor VIIa and Activated Prothrombin Complex Concentrate in a Factor VIII Inhibitor Patient
inferredcites →https://doi.org/10.1055/s-0037-1613155openalex-snapshot
Possible Synergy between Recombinant Factor VIIa and Prothrombin Complex Concentrate in Hemophilia Therapy
inferredcites →https://doi.org/10.1055/s-0037-1615947openalex-snapshot
A Cell-based Model of Hemostasis
inferredcites →https://doi.org/10.1056/nejmc1712683openalex-snapshot
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
inferredcites →https://doi.org/10.1056/nejmoa067659openalex-snapshot
Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia
inferredcites →https://doi.org/10.1056/nejmoa1104435openalex-snapshot
Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors
inferredcites →https://doi.org/10.1056/nejmoa1703068openalex-snapshot
Emicizumab Prophylaxis in Hemophilia A with Inhibitors
inferredcites →https://doi.org/10.1073/pnas.241339498openalex-snapshot
Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity
inferredcites →https://doi.org/10.1093/glycob/cwt085openalex-snapshot
N-/O-glycosylation analysis of human FVIIa produced in the milk of transgenic rabbits
inferredcites →https://doi.org/10.1097/mbc.0000000000000137openalex-snapshot
Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors
inferredcites →https://doi.org/10.1097/mbc.0000000000000525openalex-snapshot
Global Post-Authorization Safety Surveillance Study
inferredcites →https://doi.org/10.1111/bjh.14149openalex-snapshot
In vitro uptake of recombinant factor VII a by megakaryocytes with subsequent production of platelets containing functionally active drug
inferredcites →https://doi.org/10.1111/hae.12156openalex-snapshot
Results of the WIRK prospective, non‐interventional observational study of recombinant activated factor VII ( rFVIIa ) in patients with congenital haemophilia with inhibitors and other bleeding disorders
inferredcites →https://doi.org/10.1111/hae.12390openalex-snapshot
Prophylaxis with anti‐inhibitor coagulant complex improves health‐related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study
inferredcites →https://doi.org/10.1111/hae.12602openalex-snapshot
Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors
inferredcites →https://doi.org/10.1111/hae.12621openalex-snapshot
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment
inferredcites →https://doi.org/10.1111/hae.12994openalex-snapshot
TRUST trial: BAY 86‐6150 use in haemophilia with inhibitors and assessment for immunogenicity
inferredcites →https://doi.org/10.1111/hae.13088openalex-snapshot
Choosing outcome assessment tools in haemophilia care and research: a multidisciplinary perspective
inferredcites →https://doi.org/10.1111/hae.13110openalex-snapshot
Kinetic analysis and binding studies of a new recombinant human factor VII a for treatment of haemophilia
inferredcites →https://doi.org/10.1111/hae.13260openalex-snapshot
Concizumab, an anti‐tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay
inferredcites →https://doi.org/10.1111/hae.13301openalex-snapshot
PERSEPT 1: a phase 3 trial of activated eptacog beta for on‐demand treatment of haemophilia inhibitor‐related bleeding
inferredcites →https://doi.org/10.1111/hae.13357openalex-snapshot
Safety and dose‐dependency of eptacog beta (activated) in a dose escalation study of non‐bleeding congenital haemophilia A or B patients, with or without inhibitors
inferredcites →https://doi.org/10.1111/hae.13618openalex-snapshot
The effect of emicizumab prophylaxis on health‐related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study
inferredcites →https://doi.org/10.1111/j.1365-2516.2004.00924.xopenalex-snapshot
Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life‐threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor
inferredcites →https://doi.org/10.1111/j.1365-2516.2006.01284.xopenalex-snapshot
A retrospective postlicensure survey of FEIBA efficacy and safety
inferredcites →https://doi.org/10.1111/j.1365-2516.2006.01379.xopenalex-snapshot
The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01442.xopenalex-snapshot
Prophylactic treatment with activated prothrombin complex concentrate (FEIBA®) reduces the frequency of bleeding episodes in paediatric patients with haemophilia A and inhibitors
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01451.xopenalex-snapshot
Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01594.xopenalex-snapshot
Factor VIII inhibitor bypassing activity (FEIBA) – addressing safety issues
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01601.xopenalex-snapshot
Single 270 μg kg−1‐dose rFVIIa vs. standard 90 μg kg−1‐dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison
inferredcites →https://doi.org/10.1111/j.1365-2516.2008.01654.xopenalex-snapshot
Secondary prophylaxis with recombinant activated factor VII improves health‐related quality of life of haemophilia patients with inhibitors
inferredcites →https://doi.org/10.1111/j.1365-2516.2008.01956.xopenalex-snapshot
Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta‐regression
inferredcites →https://doi.org/10.1111/j.1365-2516.2008.01968.xopenalex-snapshot
Single‐dose (270 μg kg−1) recombinant activated factor VII for the treatment and prevention of bleeds in haemophilia A patients with inhibitors: experience from seven European haemophilia centres
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.02007.xopenalex-snapshot
Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.02121.xopenalex-snapshot
Effect of glycoPEGylation on factor VIIa binding and internalization
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.02179.xopenalex-snapshot
The value of early treatment in patients with haemophilia and inhibitors
inferredcites →https://doi.org/10.1111/j.1365-2516.2010.02467.xopenalex-snapshot
Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors
inferredcites →https://doi.org/10.1111/j.1365-2516.2011.02612.xopenalex-snapshot
On‐demand treatment of bleeds in haemophilia patients with inhibitors: strategies for securing and maintaining predictable efficacy with recombinant activated factor VII
inferredcites →https://doi.org/10.1111/j.1365-2796.1992.tb00546.xopenalex-snapshot
Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B
inferredcites →https://doi.org/10.1111/j.1538-7836.2006.01772.xopenalex-snapshot
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
inferredcites →https://doi.org/10.1111/j.1538-7836.2007.02663.xopenalex-snapshot
Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
inferredcites →https://doi.org/10.1111/j.1538-7836.2010.04152.xopenalex-snapshot
Recombinant human factor VIIa (rFVIIa) cleared principally by antithrombin following intravenous administration in hemophilia patients
inferredcites →https://doi.org/10.1111/j.1538-7836.2011.04344.xopenalex-snapshot
Safety and pharmacokinetics of a glycoPEGylated recombinant activated factor VII derivative: a randomized first human dose trial in healthy subjects
inferredcites →https://doi.org/10.1111/j.1538-7836.2012.04917.xopenalex-snapshot
Endothelial cell protein C receptor‐mediated redistribution and tissue‐level accumulation of factor VIIa
inferredcites →https://doi.org/10.1111/j.1600-0609.1998.tb01103.xopenalex-snapshot
Early treatment with recombinant factor VIIa results in greater efficacy with less product
inferredcites →https://doi.org/10.1111/jth.12237openalex-snapshot
40K glycoPEGylated, recombinant FVIIa: 3‐month, double‐blind, randomized trial of safety, pharmacokinetics and preliminary efficacy in hemophilia patients with inhibitors
inferredcites →https://doi.org/10.1111/jth.12458openalex-snapshot
Recommendations for performing thromboelastography/thromboelastometry in hemophilia: communication from the SSC of the ISTH
inferredcites →https://doi.org/10.1111/jth.12477openalex-snapshot
Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa‐FP)
inferredcites →https://doi.org/10.1111/jth.12628openalex-snapshot
Predicting dosing advantages of factor VIIa variants with altered tissue factor‐dependent and lipid‐dependent activities
inferredcites →https://doi.org/10.1111/jth.12864openalex-snapshot
Safety and pharmacokinetics of anti‐TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
inferredcites →https://doi.org/10.1111/jth.13141openalex-snapshot
Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
inferredcites →https://doi.org/10.1111/jth.13811openalex-snapshot
Effect of late prophylaxis in hemophilia on joint status: a randomized trial
inferredcites →https://doi.org/10.1111/jth.14203openalex-snapshot
In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents
inferredcites →https://doi.org/10.1111/jth.14204openalex-snapshot
In‐depth comparison of N‐glycosylation of human plasma‐derived factor VIII and different recombinant products: from structure to clinical implications
inferredcites →https://doi.org/10.1160/th05-07-0510openalex-snapshot
Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors
inferredcites →https://doi.org/10.1160/th11-09-0672openalex-snapshot
Factor VIIa binding to endothelial cell protein C receptor: Differences between mouse and human systems
inferredcites →https://doi.org/10.1182/blood-2006-04-017988openalex-snapshot
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
inferredcites →https://doi.org/10.1182/blood-2010-09-310706openalex-snapshot
Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection
inferredcites →https://doi.org/10.1182/blood-2011-11-393371openalex-snapshot
Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids
inferredcites →https://doi.org/10.1182/blood-2014-04-567297openalex-snapshot
The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo
inferredcites →https://doi.org/10.1182/blood-2016-05-718635openalex-snapshot
Design and characterization of an APC-specific serpin for the treatment of hemophilia
inferredcites →https://doi.org/10.1182/blood.v120.21.1114.1114openalex-snapshot
Factor VIIa-CTP, a Novel Long-Acting Coagulation Factor, Displays a Prolonged Hemostatic Effect and Augmented Pharmacokinetics and pharmacodynamics Following IV and SC Administration in Hemophilic Animal Models
inferredcites →https://doi.org/10.1182/blood.v126.23.2269.2269openalex-snapshot
Platelet-Targeted rFVIIa-Xten Improves Thrombin Generation and Fibrin Formation Compared to Recombinant FVIIa
inferredcites →https://doi.org/10.1182/blood.v128.22.1401.1401openalex-snapshot
Concizumab Promotes Hemostasis Via a TF-FVIIa Dependent Mechanism As Shown in a Rabbit Hemophilia Bleeding Model
inferredcites →https://doi.org/10.1182/blood.v61.1.36.36openalex-snapshot
The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors
inferredcites →https://doi.org/10.1182/bloodadvances.2016004143openalex-snapshot
Factor VIIa interaction with EPCR modulates the hemostatic effect of rFVIIa in hemophilia therapy: mode of its action
inferredcites →https://doi.org/10.1203/00006450-197704000-00590openalex-snapshot
A THROMBOCYTOPENIA (T) GIANT PLATELET SYNDROME WITH DEFECTIVE PLATELET AGGREGATION AND A VON WILLEBRAND (VW)-LIKE PLASMA DEFECT
inferredcites →https://doi.org/10.1203/00006450-197704000-00591openalex-snapshot
USE OF PROTHROMBIN COMPLEX CONCENTRATES (PCC) IN HEMOPHILIACS WITH INHIBITORS: LACK OF CORRELATION BETWEEN CLINICAL RESPONSE AND LABORATORY PARAMETERS
inferredcites →https://doi.org/10.2147/jbm.s61859openalex-snapshot
Mixing and administration times of bypassing agents: observations from the Dosing Observational Study in Hemophilia (DOSE)
inferredcites →https://doi.org/10.2165/11530550-000000000-00000openalex-snapshot
Glycosylation of Therapeutic Proteins
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4789895openalex-extracted
Maternal Microchimerism Promotes Tolerance Induction Toward Factor VIII in Severe Haemophilia a Children with Inhibitors
inferred← citeshttps://doi.org/10.1002/pro.3794openalex-snapshot
Engineering the serpin α1‐antitrypsin: A diversity of goals and techniques
inferred← citeshttps://doi.org/10.1002/rth2.12286openalex-snapshot
Microfluidic hemophilia models using blood from healthy donors
inferred← citeshttps://doi.org/10.1002/rth2.12576openalex-snapshot
Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety
inferred← citeshttps://doi.org/10.1002/rth2.12731openalex-snapshot
Recombinant porcine factor VIII corrects thrombin generation in vitro in plasma from patients with congenital hemophilia A and inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-031-43156-2_4openalex-snapshot
Hemophilia A: Diagnosis and Management
inferred← citeshttps://doi.org/10.1007/s00277-025-06265-6openalex-snapshot
Sequential combined bypassing therapy in haemophilia patients with high titer inhibitors: surgical experience
inferred← citeshttps://doi.org/10.1016/j.blre.2019.100613openalex-snapshot
From unfractionated heparin to pentasaccharide: Paradigm of rigorous science growing in the understanding of the in vivo thrombin generation
inferred← citeshttps://doi.org/10.1016/j.blre.2019.100618openalex-snapshot
Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine
inferred← citeshttps://doi.org/10.1016/j.blre.2020.100737openalex-snapshot
The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies
inferred← citeshttps://doi.org/10.1016/j.blre.2021.100849openalex-snapshot
Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021
inferred← citeshttps://doi.org/10.1016/j.blre.2023.101164openalex-snapshot
Nothing short of a revolution: Novel extended half-life factor VIII replacement products and non-replacement agents reshape the treatment landscape in hemophilia A
inferred← citeshttps://doi.org/10.1016/j.jconrel.2025.114520openalex-snapshot
mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia
inferred← citeshttps://doi.org/10.1016/j.jtha.2024.10.028openalex-snapshot
Examining downstream effects of concizumab in hemophilia A with a mathematical modeling approach
inferred← citeshttps://doi.org/10.1016/j.jtha.2025.07.006openalex-snapshot
Standardization of factor VIII neutralization for functional emicizumab quantification in presence of various factor VIII sources
inferred← citeshttps://doi.org/10.1016/j.rpth.2023.100179openalex-snapshot
Antithrombin-lowering in hemophilia: a closer look at fitusiran
inferred← citeshttps://doi.org/10.1016/j.rpth.2024.102637openalex-snapshot
Immune tolerance induction for inhibitor eradication in nonsevere hemophilia A: a case series
inferred← citeshttps://doi.org/10.1016/j.rpth.2024.102670openalex-snapshot
Recombinant factor VIIa: new insights into the mechanism of action through product innovation
inferred← citeshttps://doi.org/10.1016/j.rpth.2025.102877openalex-snapshot
Exploration of biomarkers for inhibitor development in persons with hemophilia A
inferred← citeshttps://doi.org/10.1016/j.rpth.2025.103212openalex-snapshot
Large deletions in the F8 gene predict immune tolerance induction failure in people with severe hemophilia A
inferred← citeshttps://doi.org/10.1016/j.thromres.2019.07.014openalex-snapshot
The use of prophylaxis in the treatment of rare bleeding disorders
inferred← citeshttps://doi.org/10.1016/j.thromres.2024.04.031openalex-snapshot
AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B
inferred← citeshttps://doi.org/10.1016/j.ymthe.2019.11.006openalex-snapshot
A Molecular Revolution in the Treatment of Hemophilia
inferred← citeshttps://doi.org/10.1016/s0140-6736(23)00284-2openalex-snapshot
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial
inferred← citeshttps://doi.org/10.1021/acsptsci.4c00560openalex-snapshot
Advances in Development of Drug Treatment for Hemophilia with Inhibitors
inferred← citeshttps://doi.org/10.1053/j.jvca.2019.01.052openalex-snapshot
Recombinant Activated Factor VII in Children Undergoing Cardiac Surgery: Remember How and Why to Use It
inferred← citeshttps://doi.org/10.1055/a-1159-4273openalex-snapshot
Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors
inferred← citeshttps://doi.org/10.1056/nejmoa2216455openalex-snapshot
Phase 3 Trial of Concizumab in Hemophilia with Inhibitors
inferred← citeshttps://doi.org/10.1080/17474086.2019.1560259openalex-snapshot
Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors
inferred← citeshttps://doi.org/10.1080/17474086.2026.2701252openalex-snapshot
Advances in treatments for hemophilia A/B with inhibitors: current treatment gaps and promising therapies
inferred← citeshttps://doi.org/10.1101/2023.10.19.563105openalex-snapshot
FVIII interacts with cell surface to regulate endothelial cell functionality
inferred← citeshttps://doi.org/10.1111/bjh.17580openalex-snapshot
Haemophilia: factoring in new therapies
inferred← citeshttps://doi.org/10.1111/hae.13845openalex-snapshot
The evolution of factor VIIa in the treatment of bleeding in haemophilia with inhibitors
inferred← citeshttps://doi.org/10.1111/hae.14253openalex-snapshot
Exploratory in vitro evaluation of thrombin generation of eptacog beta (recombinant human fviia) and emicizumab in congenital haemophilia A plasma
inferred← citeshttps://doi.org/10.1111/hae.14418openalex-snapshot
PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors
inferred← citeshttps://doi.org/10.1111/hae.14419openalex-snapshot
The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
inferred← citeshttps://doi.org/10.1111/hae.14563openalex-snapshot
Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
inferred← citeshttps://doi.org/10.1111/hae.14832openalex-snapshot
Real‐world safety and effectiveness of recombinant porcine sequence factor VIII in acquired haemophilia A: A non‐interventional, post‐authorization safety study
inferred← citeshttps://doi.org/10.1111/hae.14932openalex-snapshot
Recombinant porcine factor VIII in patients with congenital haemophilia A with inhibitors undergoing surgery: Phase 3, single‐arm, open‐label study
inferred← citeshttps://doi.org/10.1111/hae.14944openalex-snapshot
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective
inferred← citeshttps://doi.org/10.1111/hae.70083openalex-snapshot
Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors
inferred← citeshttps://doi.org/10.1111/jth.14430openalex-snapshot
Intrinsic differences between FVIIIa mimetic bispecific antibodies and FVIII prevent assignment of FVIII‐equivalence
inferred← citeshttps://doi.org/10.1136/bmjopen-2021-057018openalex-snapshot
AKATSUKI study: a prospective, multicentre, phase IV study evaluating the safety of emicizumab under and immediately after immune tolerance induction therapy in persons with congenital haemophilia A with factor VIII inhibitors
inferred← citeshttps://doi.org/10.1177/1076029620912027openalex-snapshot
Update on the Clot Waveform Analysis
inferred← citeshttps://doi.org/10.1177/10760296221143382openalex-snapshot
Absence of Effect of Emicizumab on D-Dimer Concentrations in Adult Patients with Severe Hemophilia A
inferred← citeshttps://doi.org/10.1182/blood.2022015776openalex-snapshot
Blocking hemophilic arthropathy
inferred← citeshttps://doi.org/10.1182/blood.2023021864openalex-snapshot
Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA/CFC prophylaxis: the ATLAS-PPX trial
inferred← citeshttps://doi.org/10.1182/blood.2024027008openalex-snapshot
Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study
inferred← citeshttps://doi.org/10.1182/bloodadvances.2026019931openalex-snapshot
Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study
inferred← citeshttps://doi.org/10.1590/1516-3180.2023.0102.r1.20022024openalex-snapshot
Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.2217/cer-2021-0120openalex-snapshot
Estimating the risk of thrombotic events in people with congenital hemophilia A using US claims data
inferred← citeshttps://doi.org/10.2450/2019.0026-19openalex-snapshot
Emicizumab for the treatment of haemophilia A: a narrative review.
inferred← citeshttps://doi.org/10.2478/jhp-2021-0017openalex-snapshot
Haemophilia A management with emicizumab: A survey of haematologists in the United States
inferred← citeshttps://doi.org/10.2478/jhp-2025-0019openalex-snapshot
Safety profile of concizumab: A systematic review and meta-analysis of randomised controlled trials
inferred← citeshttps://doi.org/10.25122/jml-2022-0103openalex-snapshot
Expert opinion on current and future prophylaxis therapies aimed at improving protection for people with hemophilia A
inferred← citeshttps://doi.org/10.3324/haematol.2022.281895openalex-snapshot
The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice
inferred← citeshttps://doi.org/10.3389/fbioe.2025.1684096openalex-snapshot
Transformative approaches in hemophilia management: from traditional therapies to prenatal stem cell treatment
inferred← citeshttps://doi.org/10.3389/fimmu.2019.03078openalex-snapshot
Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01219openalex-snapshot
Hemophilia A Inhibitor Subjects Show Unique PBMC Gene Expression Profiles That Include Up-Regulated Innate Immune Modulators
inferred← citeshttps://doi.org/10.3389/fimmu.2025.1668397openalex-snapshot
MHC class II presentation of FVIII-AnnexinA5 fusion proteins internalized by antigen presenting cells
inferred← citeshttps://doi.org/10.3389/fped.2023.1173549openalex-snapshot
Between Scylla and Charybdis: thrombosis in children with hemophilia
inferred← citeshttps://doi.org/10.3390/diagnostics13010013openalex-snapshot
Thromboembolic Disease in Haemophilic Patients Undergoing Major Orthopaedic Surgery: Is Thromboprophylaxis Mandatory?
inferred← citeshttps://doi.org/10.3390/jcm14010013openalex-snapshot
Laboratory Assessment of Factor VIII Inhibitors: When Is It Required? A Perspective Informed by Local Practice
inferred← citeshttps://doi.org/10.3390/medicina61040570openalex-snapshot
Venous Thromboembolism Prophylaxis in Hemophilic Patients Undergoing Total Hip or Knee Arthroplasty: Insights from a Single-Center Experience
inferred← citeshttps://doi.org/10.37903/sma.2023.3.41openalex-snapshot
ИНГИБИТОРНАЯ ФОРМА ГЕМОФИЛИИ А У ДЕТЕЙ
inferred← citeshttps://doi.org/10.70675/fb0159d0zb989z4a8dz9ca2zc27e4e44e055openalex-snapshot
Eradication of FVIII inhibitors in patients with hemophilia A
inferred← citeshttps://doi.org/10.7759/cureus.41029openalex-snapshot
Acquired Hemophilia A Masquerading as Bleeding on Anticoagulation: A Case Report Including Key Laboratory Considerations
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.